Vertex and crispr therapeutics complete submission of rolling biologics license applications (blas) to the us fda for exa-cel for the treatment of sickle cell disease and transfusion-dependent beta thalassemia

Boston & zug, switzerland--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and crispr therapeutics (nasdaq: crsp) today announced the completion of the rolling biologics license applications (blas) to the u.s. food and drug administration (fda) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (scd) and transfusion-dependent beta thalassemia (tdt).
VRTX Ratings Summary
VRTX Quant Ranking